Atorvastatin (ATR), traditionally prescribed as an antihyperlipidemic agent, has shown promising therapeutic potential beyond its primary indication, including anti-inflammatory, antioxidant, and antifungal properties. However, its clinical application is limited by poor solubility and low bioavailability.
Methods:
To address these limitations, ATR-loaded nanoparticles were prepared using Gelucire® 44/14 and Gelucire 50/13 at ratios of 1:1 and 1:3 through spray-drying. The formulations were evaluated for particle size, zeta potential, encapsulation efficiency, solubility, morphology, dissolution, and antifungal activity against four fungal strains of clinical relevance.
Results:
Increasing the Gelucire ratio from 1:1 to 1:3 significantly reduced particle size (227.30 ± 4.1 to 150.71 ± 3.8 nm) and improved encapsulation efficiency, reaching 83.53%. Dissolution was markedly enhanced, with ATR-GR 44/14 (1:3) achieving nearly complete release within 5 hours. Morphological analysis confirmed the formation of uniformly dispersed nanoparticles. Importantly, antifungal assays demonstrated that ATR-GR 44/14 (1:3) exhibited superior activity against multiple fungal strains compared with other formulations and pure ATR.
Conclusions:
Spray-dried ATR-GR nanoparticles offer an effective strategy to overcome solubility barriers while enhancing antifungal efficacy. These findings support their potential as a repurposed therapeutic platform for fungal infections and justify further preclinical and clinical investigation, including future exploration of these spray-dried systems as candidates for inhaled antifungal delivery.
RizviSAA, SalehAM. Applications of nanoparticle systems in drug delivery technology. Saudi Pharm J2018;26(1):64–70; doi: 10.1016/j.jsps.2017.10.012
5.
AltuwaijriN, FitaihiR, AlkathiriFA, et al.Assessing the Antibacterial Potential and Biofilm Inhibition Capability of Atorvastatin-Loaded Nanostructured Lipid Carriers via Crystal Violet Assay. Pharmaceuticals (Basel)2025;18(3):417.
6.
GuoY, BaldelliA, SinghA, et al.Production of high loading insulin nanoparticles suitable for oral delivery by spray drying and freeze drying techniques. Sci Rep2022;12(1):9949; doi: 10.1038/s41598-022-13092-6
7.
PatraJK, DasG, FracetoLF, et al.Nano based drug delivery systems: Recent developments and future prospects. J Nanobiotechnology2018;16(1):71; doi: 10.1186/s12951-018-0392-8
8.
SevillePC, LiH-y, LearoydTP. Spray-Dried powders for pulmonary drug delivery. Crit Rev Ther Drug Carrier Syst2007;24(4):307–360; doi: 10.1615/CritRevTherDrugCarrierSyst.v24.i4.10
9.
MalamatariM, CharisiA, MalamatarisS, et al.Spray drying for the preparation of nanoparticle-based drug formulations as dry powders for inhalation. Processes2020;8(7):788.
10.
DanielS, Ana ColetteM, VitorS, et al.Spray drying: An overview. In: RosarioP and TeresaM(eds) Biomaterials. IntechOpen, Rijeka, 2017, p. 2.
11.
NespiM, KuhnR, YenC-W, et al.Optimization of spray-drying parameters for formulation development at preclinical scale. AAPS PharmSciTech2021;23(1):28; doi: 10.1208/s12249-021-02160-1
12.
SalamaA. Spray drying as an advantageous strategy for enhancing pharmaceuticals bioavailability. Drug Deliv Transl Res2020;10(1):1–12; doi: 10.1007/s13346-019-00648-9
13.
DaniherDI, ZhuJ. Dry powder platform for pulmonary drug delivery. Particuology2008;6(4):225–238; doi: 10.1016/j.partic.2008.04.004
14.
OberCA, KalomboL, SwaiH, et al.Preparation of rifampicin/lactose microparticle composites by a supercritical antisolvent-drug excipient mixing technique for inhalation delivery. Powder Technol2013;236:132–138; doi: 10.1016/j.powtec.2012.04.057
15.
TanY, YangZ, PengX, et al.A novel bottom-up process to produce nanoparticles containing protein and peptide for suspension in hydrofluoroalkane propellants. Int J Pharm2011;413(1–2):167–173; doi: 10.1016/j.ijpharm.2011.03.069
16.
DuarteÍ, SantosJL, PintoJF, et al.Screening methodologies for the development of spray-dried amorphous solid dispersions. Pharm Res2015;32(1):222–237; doi: 10.1007/s11095-014-1457-5
17.
SinghA, Van den MooterG. Spray drying formulation of amorphous solid dispersions. Adv Drug Deliv Rev2016;100:27–50; doi: 10.1016/j.addr.2015.12.010
18.
EmamiF, Keihan ShokoohM, Mostafavi YazdiSJ. Recent progress in drying technologies for improving the stability and delivery efficiency of biopharmaceuticals. J Pharm Investig2023;53(1):35–57; doi: 10.1007/s40005-022-00610-x
19.
FahrA, LiuX. Drug delivery strategies for poorly water-soluble drugs. Expert Opin Drug Deliv2007;4(4):403–416; doi: 10.1517/17425247.4.4.403
20.
DavisM, WalkerG. Recent strategies in spray drying for the enhanced bioavailability of poorly water-soluble drugs. J Control Release2018;269:110–127; doi: 10.1016/j.jconrel.2017.11.005
21.
BarkerSA, YapSP, YuenKH, et al.An investigation into the structure and bioavailability of alpha-tocopherol dispersions in Gelucire 44/14. J Control Release2003;91(3):477–488; doi: 10.1016/s0168-3659(03)00261-x
22.
PandaM, RaoM, PandaJ, et al.Gelucire: A flexible formulation excipients. RJPT2023:955–961; doi: 10.52711/0974-360X.2023.00160
23.
BertoniS, AlbertiniB, PasseriniN. Different BCS class II Drug-Gelucire solid dispersions prepared by spray congealing: Evaluation of solid state properties and in vitro performances. Pharmaceutics2020;12(6):548; doi: 10.3390/pharmaceutics12060548
24.
da Fonseca AntunesAB, De GeestBG, VervaetC, et al.Gelucire 44/14 based immediate release formulations for poorly water-soluble drugs. Drug Dev Ind Pharm2013;39(5):791–798; doi: 10.3109/03639045.2012.709251
25.
PanigrahiK, PatraC, JenaG, et al.Gelucire: A versatile polymer for modified release drug delivery system. Futur J Pharm Sci2018;4(1):102–108; doi: 10.1016/j.fjps.2017.11.001
26.
KamalyN, YameenB, WuJ, et al.Degradable controlled-release polymers and polymeric nanoparticles: Mechanisms of controlling drug release. Chem Rev2016;116(4):2602–2663; doi: 10.1021/acs.chemrev.5b00346
27.
ZhangH, HuangX, MiJ, et al.Improvement of pulmonary absorptions of poorly absorbable drugs using Gelucire 44/14 as an absorption enhancer. J Pharm Pharmacol2014;66(10):1410–1420; doi: 10.1111/jphp.12274
28.
MelnikT, KapitanovaK, VinetL, et al.Atorvastatin-loaded spray-dried PLGA microparticles for local prevention of intimal hyperplasia: Drug release rate optimization and activity on synthetic vascular smooth muscle cells. J Drug Deliv Sci Technol2023;79:104076; doi: 10.1016/j.jddst.2022.104076
29.
DixitM, KiniAG, KulkarniPK. Preparation and characterization of microparticles of piroxicam by spray drying and spray chilling methods. Res Pharm Sci2010;5:89–97.
30.
El-BadryM, FetihG, FathyM. Improvement of solubility and dissolution rate of indomethacin by solid dispersions in Gelucire 50/13 and PEG4000. Saudi Pharm J2009;17(3):217–225; doi: 10.1016/j.jsps.2009.08.006
31.
BothEM, BoomRM, SchutyserMAI. Particle morphology and powder properties during spray drying of maltodextrin and whey protein mixtures. Powder Technol2020;363:519–524; doi: 10.1016/j.powtec.2020.01.001
32.
AltaaniB, ObaidatR, MalkawiW. Enhancement of dissolution of atorvastatin through preparation of polymeric solid dispersions using supercritical fluid technology. Res Pharm Sci2020;15(2):123–136; doi: 10.4103/1735-5362.283812
33.
GizawA, MaramiLM, TeshomeI, et al.Phytochemical Screening and In Vitro Antifungal Activity of Selected Medicinal Plants against Candida albicans and Aspergillus niger in West Shewa Zone, Ethiopia. Adv Pharmacol Pharm Sci2022;2022:3299146–20220628; doi: 10.1155/2022/3299146
34.
KeshaniS, DaudWRW, NourouziMM, et al.Spray drying: An overview on wall deposition, process and modeling. J Food Eng2015;146:152–162; doi: 10.1016/j.jfoodeng.2014.09.004
35.
ZiaeeA, AlbadarinAB, PadrelaL, et al.Spray drying of pharmaceuticals and biopharmaceuticals: Critical parameters and experimental process optimization approaches. Eur J Pharm Sci2019;127:300–318; doi: 10.1016/j.ejps.2018.10.026
36.
IslamN, Ullah KhanN, RazzaqA, et al.Self-emulsifying micelles as a drug nanocarrier system for itraconazole oral bioavailability enhancement; in vitro and in vivo assessment. Saudi Pharm J2023;31(12):101839; doi: 10.1016/j.jsps.2023.101839
37.
RoddeMS, DivaseGT, DevkarTB, et al.Solubility and bioavailability enhancement of poorly aqueous soluble atorvastatin: In vitro, ex vivo, and in vivo studies. Biomed Res Int2014;2014:463895; doi: 10.1155/2014/463895
38.
FazilM, AnsariSH, AliJ, et al.Atorvastatin solid dispersion for bioavailability enhancement. J Adv Pharm Technol Res2016;7(1):22–26; doi: 10.4103/2231-4040.169873
39.
LeunerC, DressmanJ. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm2000;50(1):47–60; doi: 10.1016/S0939-6411(00)00076-X
40.
Al-KassasR, BansalM, ShawJ. Nanosizing techniques for improving bioavailability of drugs. J Control Release2017;260:202–212; doi: 10.1016/j.jconrel.2017.06.003
41.
ShenX, WangJ, XinG. Effect of the zeta potential on the corrosion resistance of electroless nickel and PVDF composite layers using surfactants. ACS Omega2021;6(48):33122–33129; doi: 10.1021/acsomega.1c05490
42.
EndresSC, CiacchiLC, MädlerL. A review of contact force models between nanoparticles in agglomerates, aggregates, and films. J Aerosol Sci2021;153:105719; doi: 10.1016/j.jaerosci.2020.105719
43.
ZhangC, KhooSLA, SwedlundP, et al.Fabrication of spray-dried microcapsules containing noni juice using blends of maltodextrin and gum acacia: Physicochemical properties of powders and bioaccessibility of bioactives during in vitro digestion. Foods2020;9(9):1316.
44.
SamanthaSC, BrunaASM, AdrianaRM, et al.Drying by spray drying in the food industry: Micro-encapsulation, process parameters and main carriers used. Aust J Fr Stud2015;9:462–470.
45.
Novak BabičM, ZalarP, ŽenkoB, et al.Candida and Fusarium species known as opportunistic human pathogens from customer-accessible parts of residential washing machines. Fungal Biol2015;119(2–3):95–113; doi: 10.1016/j.funbio.2014.10.007
46.
XuJ. Assessing global fungal threats to humans. mLife2022;1(3):223–240; doi: 10.1002/mlf2.12036
47.
KaurS, RajputMS, DhamiBS. A study of the susceptibility of candida species isolated from human immunodeficiency virus infected patients to antifungal drugs. JAMMR2023;35(16):46–54; doi: 10.9734/jammr/2023/v35i165088
48.
BaracA, OngDSY, JovancevicL, et al.Fungi-Induced upper and lower respiratory tract allergic diseases: One entity. Front Microbiol2018;9:583; doi: 10.3389/fmicb.2018.00583
49.
NucciM, AnaissieE. Cutaneous infection by fusarium species in healthy and immunocompromised hosts: Implications for diagnosis and management. Clin Infect Dis2002;35(8):909–920; doi: 10.1086/342328
50.
MurphyC, DeplazesE, CranfieldCG, et al.The role of structure and biophysical properties in the pleiotropic effects of statins. Int J Mol Sci2020;21(22):8745; doi: 10.3390/ijms21228745
51.
ManzoniM, RolliniM. Biosynthesis and biotechnological production of statins by filamentous fungi and application of these cholesterol-lowering drugs. Appl Microbiol Biotechnol2002;58(5):555–564.
52.
ZhouY, WuW-H, ZhaoQ-B, et al.Inhibition of HMG-CoA reductase by MFS, a purified extract from the fermentation of marine fungus FusaFusarium solani FG319, and optimization of MFS production using response surface methodology. Chin J Nat Med2015;13(5):346–354; doi: 10.1016/S1875-5364(15)30025-X
53.
MnifI, HammamiI, TrikiMA, et al.Antifungal efficiency of a lipopeptide biosurfactant derived from Bacillus subtilis SPB1 vs the phytopathogenic fungus, Fusarium solani. Environ Sci Pollut Res Int2015;22(22):18137–18147; doi: 10.1007/s11356-015-5005-6
54.
TawfikSM, ZakyMF, MohammadTGM, et al.Synthesis, characterization, and in vitro antifungal activity of anionic and nonionic surfactants against crop pathogenic fungi. Journal of Industrial and Engineering Chemistry2015;29:163–171; doi: 10.1016/j.jiec.2015.03.031
55.
KhanN, Martínez-HidalgoP, IceTA, et al.Antifungal activity of bacillus species against fusarium and analysis of the potential mechanisms used in biocontrol. Front Microbiol2018;9:2363; doi: 10.3389/fmicb.2018.0236332
